| |
Deliver high performance and continuity for your next obesity trial. IQVIA’s digital ecosystem drives data accuracy, deeper insights and more proactive decision-making. Accelerate your obesity clinical research success — download the case study!
|
|
|
Precision medicine has improved the prognosis for patients with advanced non-small cell lung cancer, inspiring research aimed at developing innovative combination treatments. Access this valuable whitepaper to learn more about the effectiveness of combining antibody drug conjugates and immune checkpoint inhibitors. Download today!
|
|
| By Eric Sagonowsky Only a few days after reports emerged that the director of the FDA's cell and gene therapy office had been abruptly put on administrative leave, a new departure shows an intense period of leadership turnover at the agency isn't over. |
|
|
|
By Nick Paul Taylor The FDA has stopped new clinical trials that export American citizens’ living cells from the U.S. to “China and other hostile countries for genetic engineering and subsequent infusion” back into American patients. |
By Kevin Dunleavy The CDC’s Advisory Committee on Immunization Practices has blessed Merck’s new respiratory syncytial virus shot Enflonsia, but the decision was hardly resounding from Robert F. Kennedy Jr.’s newly formed panel of advisors. |
By Nick Paul Taylor Kymera Therapeutics sweetened news of a setback Wednesday, revealing that Sanofi is pulling back from its lead IRAK4 degrader alongside details of the selection of a follow-up prospect and a $750 million deal with Gilead. |
|
Increasing complexity within oncology clinical trials has resulted in studies that are larger and longer than in other therapeutic areas. They require new trial designs that boost efficiency, enhance flexibility and accelerate the path to approval. Access this valuable whitepaper to learn more about adaptive trials and how they deliver real-time modifications based on data.
|
|
By James Waldron Bayer-owned BlueRock Therapeutics is laying off 50 employees and shuttering its research labs in Cambridge, Mass., in order to focus its resources on its priority cell therapies, a spokesperson said. |
By Zoey Becker The commitment is part of a wider pledge to international vaccine alliance Gavi’s upcoming replenishment phase for 2026 through 2030. |
By Zoey Becker The company and ad agency 21Grams explained how to approach comedy in drug advertising during a session at this year’s Cannes Lions festival called "Laughing at Doom: Using Humor to Talk about Illness/Hellscapes." |
By Conor Hale Illumina is diving deeper into proteomics research with a $425 million plan to acquire SomaLogic, including its protein analysis platforms and certified lab services business. |
By Kevin Dunleavy Arialys has created a first-in-class precision medicine that is showing potential to become the first therapy to address the underlying cause of a rare brain disorder. |
By Fraiser Kansteiner For Lilly, building a new parenteral products and devices facility in the city of Concord was a natural evolution following the decision to throw down $470 million on a similar injectables plant at North Carolina’s famed Research Triangle Park. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," AbbVie’s Daejin Abidoye, M.D., joins us to discuss the future of antibody drug conjugates. |
|
|---|
|
|
|
Now Available On-Demand Legacy GxP systems are holding life sciences back. Learn how to modernize your data infrastructure for better compliance, scalability, and integrity. Explore cloud, AI, and automation strategies in this expert session. Register now to future-proof your records management.
|
|
| Executive SummaryBiotech innovation doesn’t slow down—and neither should your lab partner. This brief outlines how early scientific engagement, operational transparency, and integrated global lab services help reduce risk, stay on schedule, and deliver results. Whether you're navigating your first trial or scaling a growing pipeline, see how a purpose-built lab model can help you move smarter and faster. Sponsored by: IQVIA Laboratories |
| WhitepaperWe analyzed ~300 launches to identify the factors most correlated with commercial success & built a framework for peak go-to-market performance. Presented by Blue Matter, strategic consultants in the life sciences |
| Whitepaper Learn how to transform your Patient Support Programs into measurable patient-centric initiatives that inform strategic decision making. Sponsored by Herspiegel Consulting |
| Whitepaper Learn how clinical terminology helps life sciences teams streamline cohorting, reduce bias, and accelerate evidence generation. Sponsored by: IMO Health |
| |
|
